Barclays Issues Positive Forecast for Evolus (NASDAQ:EOLS) Stock Price

Evolus (NASDAQ:EOLS) had its price target upped by analysts at Barclays from $22.00 to $25.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s target price would indicate a potential upside of 74.22% from the stock’s current price.

Other research analysts also recently issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Evolus in a report on Friday, February 14th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research note on Tuesday, January 21st.

Evolus Stock Performance

NASDAQ EOLS opened at $14.35 on Wednesday. The firm has a market capitalization of $908.66 million, a P/E ratio of -15.77 and a beta of 1.33. The stock has a 50-day simple moving average of $12.72 and a two-hundred day simple moving average of $14.08. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus has a fifty-two week low of $9.25 and a fifty-two week high of $17.82.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Creative Planning lifted its holdings in Evolus by 23.7% during the third quarter. Creative Planning now owns 15,451 shares of the company’s stock valued at $250,000 after purchasing an additional 2,963 shares in the last quarter. GSA Capital Partners LLP lifted its position in shares of Evolus by 335.3% in the third quarter. GSA Capital Partners LLP now owns 120,964 shares of the company’s stock valued at $1,960,000 after acquiring an additional 93,176 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of Evolus in the third quarter worth approximately $212,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Evolus during the third quarter worth approximately $940,000. Finally, Intech Investment Management LLC acquired a new position in Evolus in the 3rd quarter valued at $228,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.